In a clinical practice guideline issued by the American Thoracic Society and published in the January issue of the American ...

Through their flaws, resilience, and humanity, these characters resonate deeply, reminding readers of shared experiences and ...

Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx"，688373.SH) announced that MRX-5, its self-developed anti-infection drug, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug ...

The following is a summary of “Demographic and clinical features of nontuberculous mycobacteria infection resulting from cosmetic procedures: a systematic review,” published in the December 2024 issue ...

ALX-1 is under clinical development by Vast Therapeutics and currently in Phase I for Bronchiectasis. According to GlobalData, Phase I drugs for Bronchiectasis have a 64% phase transition success rate ...

Sargramostim is under clinical development by Partner Therapeutics and currently in Phase III for Metastatic Melanoma.

National Jewish Health (previously National Jewish Medical and Research Center) is a research institute located in Denver, Colorado specializing in respiratory, immune and allergic research and ...